Impact of withdrawing antithrombin III administration from management of septic patients with or without disseminated intravascular coagulation

Blood Coagulation and Fibrinolysis

Volumn 25, Issue 8, 2014, Pages 795-800

  Kawano, Shinji ^a   Uchino, Shigehiko ^a   Endo, Arata ^a   Saito, Keita ^a   Iwai, Kenichi ^a   Kase, Yoichi ^a   Takinami, Masanori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antithrombin; Disseminated intravascular coagulation; Low dose antithrombin; Septic shock; Systemic inflammatory syndrome

Indexed keywords

ANTITHROMBIN III; FRESH FROZEN PLASMA; GABEXATE MESILATE;

ADULT; AGE; APACHE; ARTICLE; BACTEROIDES FRAGILIS; BILIARY TRACT INFECTION; CANDIDA; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG WITHDRAWAL; ENTEROBACTER; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PERITONITIS; PLASMA TRANSFUSION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; STREPTOCOCCUS CAPITIS; THROMBOCYTE COUNT; TREATMENT OUTCOME; AGED; COMPLICATION; CRITICAL ILLNESS; DISEASE MANAGEMENT; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG ADMINISTRATION; PATHOLOGY; SEPSIS; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTITHROMBIN III; CRITICAL ILLNESS; DISEASE MANAGEMENT; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; RETROSPECTIVE STUDIES; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84927697822     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000115     Document Type: Article

References (23)

1. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al., KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-1878.
2. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, et al., Kyber Sept Investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006;4:90-97.
3. Messori A, Vacca F, Vaiani M, Trippoli S, and the Gruppo di Studio sull'antitrombina III. Antithrombin III in patients admitted to intensive care units: a multicenter observational study. Critical Care 2002;6:447-451.
4. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G, Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Working Party. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus 2009;7:325-334.
5. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
6. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829.
7. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on 'sepsis-related problems' of the European Society of Intensive Care Medicine. Crit Care Med 1998;26:1793-1800.
8. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, et al., Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006;34:625-631.
9. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Doubleblind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104:882-888.
10. Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998;24:336-342.
11. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, et al. Antithrombin III in patients with severe sepsis. A randomized, placebocontrolled, double blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998;24:663-672.
12. Lee WL, Downey GP. Coagulation inhibitors in sepsis and disseminated intravascular coagulation. Intensive Care Med 2000;26:1701-1706.
13. Afshari A, Wetterslev J, Brok J, Møller A. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ 2007;335:1248-1251.
14. Freeman BD, Zehnbauer BA, Buchman TG. A meta-analysis of controlled trialsofanticoagulant therapies inpatients with sepsis. Shock 2015;20:5-9.
15. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009;145:24-33.
16. Gando S, Sawamura A, Hayakawa M, Hoshino H, Kubota N, Oshiro A. First day dynamic changes in antithrombin III activity after supplementation have a predictive value in critically ill patients. Am J Hematol 2006;81:907-914.
17. Sawamura A, Gando S, Hayakawa M, Hoshino H, Kubota N, Sugano M. Effects of antithrombin III in patients with disseminated intravascular coagulation diagnosed by newly developed diagnostic criteria for critical illness. Clin Appl Thromb Hemost 2009;15:561-566.
18. Iba T, Saito D, Wada H, Asakura H. Efficacy and bleeding riskofantithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thromb Res 2012;130:129-133.
19. Iba T, Nagaoka I, Marcel B. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thromb Res 2013;131:383-389.
20. Dickneite G, Paques EP. Reduction of mortality with antithrombin III in septicemic rats: a study of Kleibsiella pneumoniae induced sepsis. Thromb Haemost 1993;69:98-102.
21. Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 1998;89:233-241.
22. Iba T, Kidokoro A. High-dose antithrombin therapy for sepsis: mechanisms of action. Shock 2002;18:389-394.
23. Aibiki M, Fukuoka N, Nishiyama T, Maekawa S, Shirakawa Y. Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: a pharmacokinetic study. Shock 2007;28:141-147.